SK287261B6 - Oslabená ľudská rotavírusová populácia, spôsob jej výroby, vakcínový prostriedok s jej obsahom a jej použitie - Google Patents

Oslabená ľudská rotavírusová populácia, spôsob jej výroby, vakcínový prostriedok s jej obsahom a jej použitie Download PDF

Info

Publication number
SK287261B6
SK287261B6 SK243-2002A SK2432002A SK287261B6 SK 287261 B6 SK287261 B6 SK 287261B6 SK 2432002 A SK2432002 A SK 2432002A SK 287261 B6 SK287261 B6 SK 287261B6
Authority
SK
Slovakia
Prior art keywords
rotavirus
vaccine composition
vaccine
nucleotide sequence
population
Prior art date
Application number
SK243-2002A
Other languages
English (en)
Slovak (sk)
Other versions
SK2432002A3 (en
Inventor
Brigitte Desiree Alberte Colau
Francoise Denamur
Isabelle Knott
Annick Poliszczak
Georges Thiry
Velde Vincent Vande
Original Assignee
Smithkline Beecham Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9919468.0A external-priority patent/GB9919468D0/en
Priority claimed from GBGB9927336.9A external-priority patent/GB9927336D0/en
Application filed by Smithkline Beecham Biologicals S.A. filed Critical Smithkline Beecham Biologicals S.A.
Publication of SK2432002A3 publication Critical patent/SK2432002A3/sk
Publication of SK287261B6 publication Critical patent/SK287261B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12351—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Birds (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SK243-2002A 1999-08-17 2000-08-15 Oslabená ľudská rotavírusová populácia, spôsob jej výroby, vakcínový prostriedok s jej obsahom a jej použitie SK287261B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9919468.0A GB9919468D0 (en) 1999-08-17 1999-08-17 Vaccine
GBGB9927336.9A GB9927336D0 (en) 1999-11-18 1999-11-18 Vaccine
PCT/EP2000/007965 WO2001012797A2 (en) 1999-08-17 2000-08-15 Method of separating rotavirus variants and live attenuated rotavirus vaccine

Publications (2)

Publication Number Publication Date
SK2432002A3 SK2432002A3 (en) 2002-09-10
SK287261B6 true SK287261B6 (sk) 2010-04-07

Family

ID=26315853

Family Applications (1)

Application Number Title Priority Date Filing Date
SK243-2002A SK287261B6 (sk) 1999-08-17 2000-08-15 Oslabená ľudská rotavírusová populácia, spôsob jej výroby, vakcínový prostriedok s jej obsahom a jej použitie

Country Status (42)

Country Link
US (4) US7285280B1 (bg)
EP (1) EP1212084B1 (bg)
JP (3) JP2003507040A (bg)
KR (1) KR100695599B1 (bg)
CN (1) CN100379451C (bg)
AP (1) AP1768A (bg)
AR (1) AR029643A1 (bg)
AT (1) ATE327765T1 (bg)
AU (1) AU767885B2 (bg)
BG (1) BG65314B1 (bg)
BR (1) BRPI0013357B8 (bg)
CA (1) CA2379196C (bg)
CO (1) CO5580165A1 (bg)
CY (2) CY1106103T1 (bg)
CZ (1) CZ302173B6 (bg)
DE (2) DE60028390T2 (bg)
DK (1) DK1212084T3 (bg)
DZ (1) DZ3219A1 (bg)
EA (1) EA005952B1 (bg)
ES (1) ES2260046T3 (bg)
FR (1) FR06C0018I2 (bg)
HK (1) HK1046860B (bg)
HU (2) HU228975B1 (bg)
IL (3) IL147926A0 (bg)
LU (1) LU91251I2 (bg)
MA (1) MA25489A1 (bg)
MX (1) MXPA02001648A (bg)
MY (1) MY133158A (bg)
NL (1) NL300233I2 (bg)
NO (2) NO328112B1 (bg)
NZ (1) NZ517131A (bg)
OA (1) OA12312A (bg)
PE (1) PE20010487A1 (bg)
PL (1) PL205550B1 (bg)
PT (1) PT1212084E (bg)
SI (1) SI1212084T1 (bg)
SK (1) SK287261B6 (bg)
TR (1) TR200200420T2 (bg)
TW (1) TWI283270B (bg)
UA (1) UA77388C2 (bg)
UY (1) UY26297A1 (bg)
WO (1) WO2001012797A2 (bg)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1212084T3 (da) * 1999-08-17 2006-07-10 Glaxosmithkline Biolog Sa Fremgangsmåde til adskillelse af rotavirus-varianter samt levende, svækket rotavirus-vaccine
US6592869B2 (en) * 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
GB0020089D0 (en) * 2000-08-15 2000-10-04 Smithkline Beecham Biolog Vaccine Composition
KR20030026654A (ko) * 2001-09-26 2003-04-03 주식회사 씨트리 인간 로타바이러스의 활성을 저해하는 항체의 생산용 항원및 그의 제조방법과 이용
EP2272532B1 (en) * 2003-09-02 2016-02-10 GlaxoSmithKline Biologicals S.A. Rotavirus vaccine
GB0414787D0 (en) 2004-07-01 2004-08-04 Glaxosmithkline Biolog Sa Method
GB0503337D0 (en) * 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
EP1915173A2 (en) * 2005-08-17 2008-04-30 GlaxoSmithKline Biologicals S.A. Rotavirus vaccine inducing heterotypic cross protection
EP2360175B1 (en) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
KR101051986B1 (ko) * 2006-09-28 2011-07-26 중앙대학교 산학협력단 인간로타바이러스 및 이를 이용한 백신 조성물
CA2668417A1 (en) * 2006-11-03 2008-05-15 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
EP2236617A1 (en) 2009-03-31 2010-10-06 Leukocare Ag Methods of terminal sterilization of biofunctional compositions
CN102695522B (zh) 2009-05-12 2016-10-19 美国政府(由卫生和人类服务部、疾病控制和预防中心的部长所代表) 新的人轮状病毒株和疫苗
CN102470170B (zh) * 2009-07-13 2015-03-18 巴拉特生物技术国际有限公司 用作轮状病毒疫苗的组合物及其方法
FR2960781B1 (fr) * 2010-06-07 2013-11-22 Sanofi Pasteur Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue
JP6126684B2 (ja) 2012-04-23 2017-05-10 バハラ バイオテック インターナショナル リミテッド 新規なロタウイルスワクチン組成物及び同組成物を調製する方法
NZ631348A (en) * 2012-08-27 2017-02-24 Murdoch Childrens Res Inst Modified human rotaviruses and uses therefor
LT3299384T (lt) * 2015-05-21 2021-12-27 Xiamen University Sutrumpintas rotaviruso vp4 baltymas ir jo pritaikymas
WO2017062246A1 (en) 2015-10-05 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human rota virus g9p[6] strain and use as a vaccine
RU2018126322A (ru) * 2015-12-18 2020-01-20 Мерк Шарп И Доум Корп. Термически стабильные ротавирусные вакцинные композиции и способы их применения
MA44557B1 (fr) 2016-06-16 2021-11-30 Bharat Biotech Int Ltd Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer
GB201614799D0 (en) * 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
CN110856493B (zh) * 2018-08-20 2022-02-25 中国烟草总公司黑龙江省公司牡丹江烟草科学研究所 一种植物病毒弱毒疫苗组合物、弱毒疫苗保存方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5927323B2 (ja) * 1976-10-12 1984-07-05 花王株式会社 歯みがき組成物
US4341763A (en) * 1981-03-10 1982-07-27 Smithkline-Rit Methods of vaccinating humans against rotavirus infection
US4571385A (en) * 1983-06-27 1986-02-18 The United States Of America As Represented By The Department Of Health And Human Services Genetic reassortment of rotaviruses for production of vaccines and vaccine precursors
EP0152295B1 (en) * 1984-02-09 1991-03-20 Royal Children's Hospital Research Foundation Live attenuated human rotavirus vaccine and preparation thereof
US5626851A (en) * 1987-11-30 1997-05-06 The Wistar Institute Of Anatomy And Biology Rotavirus reassortant vaccine
ES2121841T3 (es) * 1990-11-16 1998-12-16 Childrens Hosp Medical Center Una vacuna para proporcionar proteccion inmunologica contra enfermedades de rotavirus en humanos.
US5471385A (en) * 1992-05-21 1995-11-28 Tsubakimoto Chain Co. Routeless guiding method for moving body
US5773009A (en) * 1994-04-15 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services Rotavirus strain G9P11
US7150984B2 (en) * 1994-07-11 2006-12-19 The United States Of America As Represented By The Department Of Health And Human Services Attenuated human rotavirus vaccine
CA2266486C (en) * 1996-09-26 2007-09-25 Merck & Co., Inc. Rotavirus vaccine formulations
US6403098B1 (en) * 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
DK1212084T3 (da) * 1999-08-17 2006-07-10 Glaxosmithkline Biolog Sa Fremgangsmåde til adskillelse af rotavirus-varianter samt levende, svækket rotavirus-vaccine

Also Published As

Publication number Publication date
FR06C0018I2 (fr) 2007-04-27
PL354135A1 (en) 2003-12-29
CO5580165A1 (es) 2005-11-30
CZ302173B6 (cs) 2010-11-24
HUS1300072I1 (hu) 2019-11-28
LU91251I2 (fr) 2006-08-14
NO2010011I2 (no) 2015-02-02
JP2007319164A (ja) 2007-12-13
AR029643A1 (es) 2003-07-10
CY1106103T1 (el) 2010-07-28
MY133158A (en) 2007-10-31
HK1046860B (zh) 2006-10-06
JP2011045374A (ja) 2011-03-10
DK1212084T3 (da) 2006-07-10
HUP0203335A3 (en) 2004-07-28
AP2002002424A0 (en) 2002-03-31
MA25489A1 (fr) 2002-07-01
US20090130145A1 (en) 2009-05-21
PE20010487A1 (es) 2001-06-23
US20080063662A1 (en) 2008-03-13
EA200200142A1 (ru) 2002-08-29
US7790180B2 (en) 2010-09-07
LU91251I9 (bg) 2018-12-31
NZ517131A (en) 2003-07-25
OA12312A (en) 2006-05-12
UA77388C2 (uk) 2006-12-15
US7285280B1 (en) 2007-10-23
DE60028390D1 (de) 2006-07-06
HK1046860A1 (en) 2003-01-30
AU6996100A (en) 2001-03-13
DE60028390T2 (de) 2006-11-02
EA005952B1 (ru) 2005-08-25
WO2001012797A3 (en) 2001-08-02
IL147926A (en) 2008-03-20
PT1212084E (pt) 2006-07-31
SI1212084T1 (sl) 2006-08-31
CY2006004I2 (el) 2009-11-04
BG65314B1 (bg) 2008-01-31
CA2379196C (en) 2015-05-26
BRPI0013357B8 (pt) 2021-05-25
MXPA02001648A (es) 2002-08-06
US20080057082A1 (en) 2008-03-06
KR20020092344A (ko) 2002-12-11
EP1212084A2 (en) 2002-06-12
TR200200420T2 (tr) 2002-05-21
US7790179B2 (en) 2010-09-07
CZ2002522A3 (cs) 2002-05-15
BRPI0013357B1 (pt) 2016-08-02
NL300233I2 (nl) 2006-10-02
IL188686A0 (en) 2008-04-13
IL147926A0 (en) 2002-08-14
JP5474720B2 (ja) 2014-04-16
CN100379451C (zh) 2008-04-09
EP1212084B1 (en) 2006-05-31
CY2006004I1 (el) 2009-11-04
BR0013357A (pt) 2002-04-30
NO20020763L (no) 2002-04-16
PL205550B1 (pl) 2010-04-30
SK2432002A3 (en) 2002-09-10
HU228975B1 (en) 2013-07-29
DZ3219A1 (fr) 2001-02-22
NL300233I1 (nl) 2006-09-01
CN1379683A (zh) 2002-11-13
JP2003507040A (ja) 2003-02-25
HUP0203335A1 (hu) 2003-02-28
TWI283270B (en) 2007-07-01
NO20020763D0 (no) 2002-02-15
KR100695599B1 (ko) 2007-03-14
UY26297A1 (es) 2001-03-16
AP1768A (en) 2007-08-16
WO2001012797A2 (en) 2001-02-22
FR06C0018I1 (bg) 2006-07-21
NO2010011I1 (no) 2010-06-07
BG106417A (bg) 2003-04-30
AU767885B2 (en) 2003-11-27
DE122006000026I1 (de) 2006-10-12
CA2379196A1 (en) 2001-02-22
NO328112B1 (no) 2009-12-07
ES2260046T3 (es) 2006-11-01
ATE327765T1 (de) 2006-06-15

Similar Documents

Publication Publication Date Title
US7790180B2 (en) Immunogenic composition of a homogeneous live attenuated human rotavirus population
CA2619751C (en) Vaccine
EP2272532B1 (en) Rotavirus vaccine
US7579008B2 (en) Immunization with an attenuated human rotavirus
EP1676586B1 (en) Method of separating rotavirus variants and live attenuated rotavirus vaccine
ZA200601771B (en) Vaccine

Legal Events

Date Code Title Description
SPCF Filing of an spc

Free format text: PRODUCT NAME: ROTAVIRUSOVA VAKCINA, ZIVY OSLABENY LUDSKY ROZAVIRUSOVY KMEN RIX 4414; REGISTRATION NO/DATE: EU/1/05/330/001 - EU/1/05/330/004 20060221

Spc suppl protection certif: 4-2010

Filing date: 20100528

TC4A Change of owner's name

Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A., RIXENSART, BE

Effective date: 20100907

SPCG Grant of an spc

Free format text: PRODUCT NAME: ZIVY OSLABENY L'UDSKY ROZAVIRUSOVY KMEN RIX 4414; REGISTRATION NO/DATE: EU/1/05/330/001 - EU/1/05/330/004 20060221

Spc suppl protection certif: 98 4-2010

Filing date: 20100528

Expiry date: 20200816

Extension date: 20210221

SPCM Change of validity term of an spc as amended by art. 17 (2) of ec reg. no. 1610/96 and art. 18 of ec reg. no. 469/2009

Free format text: PRODUCT NAME: ZIVY OSLABENY L'UDSKY ROZAVIRUSOVY KMEN RIX 4414; REGISTRATION NO/DATE: EU/1/05/330/001 - EU/1/05/330/004 20060221

Spc suppl protection certif: 98 4-2010

Filing date: 20100528

MK4A Patent expired

Expiry date: 20200815

SPCE Expiry of an spc

Free format text: PRODUCT NAME: ZIVY OSLABENY LUDSKY ROTAVIRUSOVY KMEN RIX 4414

Spc suppl protection certif: 98

Effective date: 20210223